Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-08-06
DOI
10.3389/fphar.2019.00872
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Utilization of the validated Psoriasis Epidemiology Screening Tool (PEST) to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry
- (2019) P. J. Mease et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
- (2019) Vibeke Strand et al. Journal of Comparative Effectiveness Research
- Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Meta-Analysis
- (2019) Ahmed Mourad et al. JOURNAL OF RHEUMATOLOGY
- Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
- (2018) Philip Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects
- (2018) Sauzanne Khalilieh et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
- (2018) Marie-Astrid Boutet et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
- (2018) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis
- (2018) Lu Yang et al. Arthritis & Rheumatology
- Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
- (2018) Ahmed A. Suleiman et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials
- (2018) Philip Mease et al. ARTHRITIS CARE & RESEARCH
- Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial
- (2018) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review
- (2018) Maxime Sondag et al. CLINICAL RHEUMATOLOGY
- Tildrakizumab for the treatment of psoriasis
- (2018) Rodney Sinclair et al. Expert Review of Clinical Immunology
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases
- (2018) Lazaros I. Sakkas et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis
- (2017) Dongze Wu et al. RHEUMATOLOGY
- Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
- (2017) P. Kawalec et al. RHEUMATOLOGY INTERNATIONAL
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
- (2016) Yanli Zhuang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a
- (2016) Ka Lun Cheung et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
- (2015) Michele W L Teng et al. NATURE MEDICINE
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex
- (2014) J. F. Wright et al. JOURNAL OF IMMUNOLOGY
- Pharmacologic Inhibition of ROR t Regulates Th17 Signature Gene Expression and Suppresses Cutaneous Inflammation In Vivo
- (2014) J. Skepner et al. JOURNAL OF IMMUNOLOGY
- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice
- (2014) I. Khmaladze et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
- (2014) Lisa GM van Baarsen et al. ARTHRITIS RESEARCH & THERAPY
- The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
- (2014) Roberto Lande et al. Nature Communications
- IL-17 and TNF Synergistically Modulate Cytokine Expression while Suppressing Melanogenesis: Potential Relevance to Psoriasis
- (2013) Claire Q.F. Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
- (2013) Philip J. Mease et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
- (2013) Michelle A. Lowes et al. TRENDS IN IMMUNOLOGY
- Th17 and Th22 cells in psoriatic arthritis and psoriasis
- (2013) Helen Benham et al. ARTHRITIS RESEARCH & THERAPY
- IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
- (2012) Jonathan P Sherlock et al. NATURE MEDICINE
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-17C Promotes Th17 Cell Responses and Autoimmune Disease via Interleukin-17 Receptor E
- (2011) Seon Hee Chang et al. IMMUNITY
- Signaling of interleukin-17 family cytokines in immunity and inflammation
- (2010) Seon Hee Chang et al. CELLULAR SIGNALLING
- Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
- (2009) C. Johansen et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
- (2008) Alexa B. Kimball ARCHIVES OF DERMATOLOGY
- Regulation of inflammatory responses by IL-17F
- (2008) Xuexian O. Yang et al. JOURNAL OF EXPERIMENTAL MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started